Q3 2025 Fulgent Genetics Inc Earnings Call Transcript
Key Points
- Fulgent Genetics Inc (FLGT) reported strong third-quarter results with nearly $84 million in Laboratory Services revenue, showing sequential and year-over-year growth.
- The company has made significant progress in its Therapeutic Development pipeline, with FID-007 showing promising results in a Phase 2 clinical trial.
- Fulgent Genetics Inc (FLGT) has launched new products, including an ultra-rapid whole genome sequencing service and an expanded Beacon Carrier Screening service, enhancing its product offerings.
- The company has developed its own proprietary image management system, Ezopath, to improve efficiency and integrate AI tools in digital pathology.
- Fulgent Genetics Inc (FLGT) has raised its full-year 2025 revenue outlook to $325 million, representing a 15% year-over-year growth, and expects non-GAAP gross margins to exceed 40%.
- Anatomic pathology revenue was down 7.6% sequentially due to timing of collections, although it was up year over year.
- The company reported a GAAP loss of $6.6 million for the third quarter, although this was an improvement from the previous quarter.
- Non-GAAP operating margin was negative at minus 4.2%, indicating ongoing challenges in achieving profitability.
- The transition to new billing software caused timing issues in collections, impacting revenue recognition in the quarter.
- COVID-19 testing revenue is expected to remain negligible, impacting the company's overall revenue mix.
Greetings and welcome to the Fulgent Genetics Q3 2025 conference call and webcast. (Operator Instructions) As a reminder, this conference is being recorded. It's now my pleasure to turn the call over to Lauren Sloan, Investor relations. Please go ahead, Lauren.
Good morning and welcome to Fulgent third-quarter 2025 financial results conference call. On the call are Ming Hsieh, Chief Executive Officer; Paul Kim, Chief Financial Officer; and Brandon Perthuis, Chief Commercial Officer.
The company's press release discussing the financial results is available on the Investor Relations section of the company's website, ir.fulgentgenetics.com. A replay of this call will be available shortly after the call concludes on the Investor Relations section of the company's website.
Management's prepared remarks and answers to your questions on today's call will contain forward-looking statements. These forward-looking statements represent management's estimates based on current views, expectations,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
